Aspira Pathlab & Diagnostics Limited
Aspira Pathlab & Diagnostics Limited Fundamental Analysis
Aspira Pathlab & Diagnostics Limited (ASPIRA.BO) shows weak financial fundamentals with a PE ratio of 43.34, profit margin of 5.68%, and ROE of 11.02%. The company generates $0.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 53.9/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ASPIRA.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakASPIRA.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateASPIRA.BO shows balanced valuation metrics.
Growth Score
ModerateASPIRA.BO shows steady but slowing expansion.
Financial Health Score
ExcellentASPIRA.BO maintains a strong and stable balance sheet.
Profitability Score
WeakASPIRA.BO struggles to sustain strong margins.
Key Financial Metrics
Is ASPIRA.BO Expensive or Cheap?
P/E Ratio
ASPIRA.BO trades at 43.34 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ASPIRA.BO's PEG of -0.75 indicates potential undervaluation.
Price to Book
The market values Aspira Pathlab & Diagnostics Limited at 4.14 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 19.84 times EBITDA. This signals the market has high growth expectations.
How Well Does ASPIRA.BO Make Money?
Net Profit Margin
For every $100 in sales, Aspira Pathlab & Diagnostics Limited keeps $5.68 as profit after all expenses.
Operating Margin
Core operations generate 5.54 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.02 in profit for every $100 of shareholder equity.
ROA
Aspira Pathlab & Diagnostics Limited generates $6.83 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Aspira Pathlab & Diagnostics Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Aspira Pathlab & Diagnostics Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
ASPIRA.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
43.34
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.75
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.14
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.47
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.22
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.38
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How ASPIRA.BO Stacks Against Its Sector Peers
| Metric | ASPIRA.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 43.34 | 28.54 | Worse (Expensive) |
| ROE | 11.02% | 738.00% | Weak |
| Net Margin | 5.68% | -43982.00% (disorted) | Weak |
| Debt/Equity | 0.22 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 2.38 | 2806.01 | Strong Liquidity |
| ROA | 6.83% | -14624.00% (disorted) | Weak |
ASPIRA.BO outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Aspira Pathlab & Diagnostics Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation